Current status and future trends of the global burden of MASLD.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the most widespread global chronic liver disease, affecting over 30% of adults. MASLD has effects beyond adverse liver outcomes, affecting cardiovascular disease, chronic kidney disease, and various extrahepatic cancers. The economic burden of MASLD is substantial, exceeding $100 billion in the USA alone, with liver transplantation being a significant contributor to healthcare costs. Regional variations in MASLD prevalence occur with the highest rates in Latin America and the Middle East, highlighting the need for culturally tailored interventions and a comprehensive global effort. Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most common chronic liver disease globally, affecting more than a third of the world's adult population. This comprehensive narrative review summarizes the global incidence and prevalence rates of MASLD and its related adverse hepatic and extrahepatic outcomes. We also discuss the substantial economic burden of MASLD on healthcare systems, thus further highlighting the urgent need for global efforts to tackle this common and burdensome liver condition. We emphasize the clinical relevance of early interventions and a holistic approach that includes public health strategies to reduce the global impact of MASLD. [ABSTRACT FROM AUTHOR]